Proteins for Targeting and Delivering Therapeutic Nanomaterials

Abstract submission deadline

closed (14 October 2022)

Manuscript submission deadline

closed (15 December 2022)

Viewed by

1437

Topic Information

Dear Colleagues, 

The increasing incidence of cancer has turned research into new experimental treatments into a crucial issue in the fight against this devastating disease. In this sense, nanomaterials have greatly advanced in recent decades because of their tremendous therapeutic potential. Although some of the nanosystems base their activity on passive targeting taking advantage of the increased production of blood vessels and their permeability in tumor areas (known as the EPR effect), the design of these nanosystems without any specific vectorization presents some drawbacks, such as a non-specific administration of the drug and potential accumulation in undesired areas, which increase the potential side-effects associated with the therapeutic treatments. In the search for potential solutions to the lack of specificity of therapeutic agents, encapsulation and/or active targeting is being developed focusing on the use of specific molecules such as peptides, antibodies or proteins incorporated on the surface of the nanosystems, as an alternative strategy that allows greater efficiency in the vectorization toward tumors. Proteins are very good candidates for the design of this kind of selective material because of their biocompatibility, easy functionalization, high loading capacity, and their potential active targeting, as a wide variety of cancer cells upregulate some proteins, accelerating their cellular uptake and overexpressing their receptors. Therefore, the use of proteins as vehicles for delivery is a successful strategy for introducing therapeutic agents based on nanomaterials, and a wide variety of formulations based on proteins have been demonstrated to target cancer cells directly and selectively. Moreover, the functionalization of nanomaterials with proteins usually leads to molecular interactions between proteins and the tumor microenvironment, not only improving the selectivity of the systems, but also enhancing the anticancer action both in vitro and in vivo. Therefore, this Special Issue will highlight the current state of the art in the use of proteins as target and delivery molecules incorporating different nanomaterials, focusing on the future prospects of this kind of systems for improving current therapies in a preclinical context.

Dr. Diana Díaz-García
Prof. Dr. Santiago Gómez-Ruiz
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biology biology	3.6	5.7	2012	16.4 Days	CHF 2700
Cancers cancers	4.5	8.0	2009	17.4 Days	CHF 2900
Current Oncology curroncol	2.8	3.3	1994	19.8 Days	CHF 2200
Nanomaterials nanomaterials	4.4	8.5	2010	14.1 Days	CHF 2400
Onco onco	-	-	2021	27.8 Days	CHF 1000

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers